Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine plus atorvastatin versus each alone for prevention of contrast-induced nephropathy
IRCT20180417039347N1Phase 3Completed
- Sponsor
- Zahedan University of Medical Sciences
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in contrast-induced nephropathy (CIN) comparing N-acetylcysteine + atorvastatin, N-acetylcysteine alone and Atorvastatin alone (3 arms). Primary endpoint: Incidence of contrast-induced nephropathy. Started Aug 2020; status: completed.
02
Drugs
acetylcysteineatorvastatin
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on IRCT20180417039347N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180417039347N1.